Information Provided By:
Fly News Breaks for October 25, 2018
BSX
Oct 25, 2018 | 07:35 EDT
Canaccord analyst Jason Mills noted Boston Scientific reported solid Q3 results and said there was nothing in the report to imply a loss of momentum. The analyst believes the company will enter 2019 with its best fundamentals in its history and is very well positioned to deliver organic revenue growth above its peers. Mills reiterated his Buy rating and raised his price target to $42 from $40 on Boston Scientific shares.
News For BSX From the Last 2 Days
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.